EMA Validates Valneva's Lyme Vaccine MAA; Phase 3 Shows >70% Efficacy
VALN sits 48% above its 52-week low of $4.75 on elevated volume (36× avg).
Summary
Valneva and Pfizer's Lyme disease vaccine candidate has been accepted for review by the European Medicines Agency, based on Phase 3 data showing over 70% efficacy.
Key Events · Product Development and Regulatory · VALN
-
EMA Validates MAA
The European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the Lyme disease vaccine candidate developed with Pfizer, and will begin its assessment.
-
Phase 3 Efficacy >70%
The Phase 3 VALOR trial showed efficacy of more than 70% in preventing Lyme disease in individuals aged 5 and older, with no safety concerns identified.
-
First-in-Class Opportunity
There are currently no approved human vaccines for Lyme disease, and over 200 million people live in Lyme disease risk areas in Europe, representing a significant market opportunity.
-
Regulatory Review Timeline
The EMA review process will now proceed, with approval timing dependent on the agency's assessment of the application.
Analysis · VALN · Life Sciences
The EMA has accepted the Marketing Authorization Application for PF-07307405, the Lyme disease vaccine candidate from Valneva and Pfizer, triggering the formal review process. This is a major regulatory milestone for a vaccine with no approved competitors and a large addressable market in Europe. The Phase 3 VALOR trial demonstrated over 70% efficacy with no safety concerns, supporting a strong approval case. For Valneva, which reported a tripling of its net loss just yesterday, this progress on its lead pipeline asset is a critical positive development that could transform its commercial outlook if approved.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.6% of the 978 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VALN was trading at $7.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $536.7M. The 52-week trading range was $4.75 to $12.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.